Abstract:Liver fibrosis, a condition defined by excessive accumulation of extracellular matrix, is triggered by the activation of hepatic stellate cells (HSCs). Astaxanthin (ASTX), a xanthophyll carotenoid, has multiple protective properties against nonalcoholic steatohepatitis (NASH). To investigate anti‐fibrogenic functions of ASTX, we used LX‐2, a human HSC cell line, and primary HSCs isolated from C57BL/6J mice in this study. Increases in the production of reactive oxygen species by transforming growth factor β 1(TGF‐β1) or tert‐butyl hydroperoxide was significantly attenuated by 25 μM ASTX in LX‐2 cells. Pretreatment with ASTX significantly decreased TGF‐β1‐induced mRNA abundance of α‐smooth muscle actin (α‐SMA) and collagen 1 α1 (Col1α1) and Western blot confirmed the reduction in α‐SMA expression by ASTX in LX‐2 cells. The nuclear translocation of major transcription factors transducing TGF‐β1 signal, i.e., Smad‐3 and Krueppel‐like factor 6 (KLF‐6), was noticeably inhibited by ASTX in LX‐2 cells. ASTX also significantly repressed the expression of α‐SMA and restored superoxide dismutase 2 expression in activated primary mouse HSCs. In conclusion, our study demonstrates that ASTX exerts anti‐fibrogenic and antioxidant effects in HSCs in vitro by repressing the activation of Smad‐3 and KLF6 by TGF‐β1, suggesting a potential role of ASTX in the prevention of NASH. Grant Funding Source: USDA AFRI 2012–67018‐19290

Astaxanthin inhibits TGF‐β1‐induced fibrogenic gene expression by inhibiting the activation of Smad3 and KLF‐6 pathways in LX‐2 and primary mouse hepatic stellate cells